Ramelteon and Escitalopram
PreclinicalSmall molecule
Ramelteon and Escitalopram is one of 32 small molecule programs targeting Panic Disorder. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
41 competitors in Panic Disorder
#DrugCompanyPhaseTrials
1Brintellix
TakedaApproved
Cymbalta
Alnylam PharmaceuticalsApproved
Atarax
PfizerApproved
Paxil CR
GSKApproved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lexapro
AbbVieApproved
Celexa
AbbVieApproved
Klonopin
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Zoloft
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ramelteon and Escitalopram. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMilton S. Hershey Medical Center